{
    "eid": "2-s2.0-85057175872",
    "title": "Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia",
    "cover-date": "2019-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biochemistry",
            "@code": "1303",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Neurology (clinical)",
            "@code": "2728",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cellular and Molecular Neuroscience",
            "@code": "2804",
            "@abbrev": "NEUR"
        }
    ],
    "keywords": [
        "Deficit schizophrenia",
        "Depression",
        "Immune",
        "Inflammation",
        "Physio-somatic",
        "Tryptophan catabolites"
    ],
    "authors": [
        "Buranee Kanchanatawan",
        "Sira Sriswasdi",
        "Michael Maes"
    ],
    "citedby-count": 19,
    "ref-count": 76,
    "ref-list": [
        "TensorFlow: Large-scale machine learning on heterogenous systems",
        "Is quality of life associated with cognitive impairment in schizophrenia?",
        "Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia",
        "Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression",
        "The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations",
        "Needs and quality of life among patients with schizophrenia in five European centres: what is the impact of global functioning scores?",
        "Controlling the false discovery rate: a practical and powerful approach to multiple testing",
        "Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis",
        "Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug na\u00efve first episode psychosis",
        "Quality of life in schizophrenic patients",
        "Factors associated with low quality of life in schizophrenia",
        "Prediction of quality of life in Asian patients with schizophrenia: A cross-sectional pilot study",
        "Disrupted prediction-error signal in psychosis: Evidence for an associative account of delusions",
        "Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries",
        "A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis",
        "The health-related quality of life for patients with Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS)",
        "Subject and observer-rated quality of life in schizophrenia",
        "Explaining the symptoms of schizophrenia: abnormalities in the awareness of action",
        "Schizophrenia and quality of life: how important are symptoms and functioning?",
        "Social functioning and quality of life in schizophrenia patients --relationship with symptomatic remission and duration of illness",
        "Gender differences in schizophrenia",
        "The assessment of anxiety states by rating",
        "A rating scale for depression",
        "Negative symptoms and cognitive deficits: what is the nature of their relationship?",
        "Neuropsychological status of subjects at high risk for a first episode of psychosis",
        "Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia",
        "Deficit schizophrenia is characterized by defects in IgM-mediated responses to tryptophan catabolites (TRYCATs): A paradigm shift towards defects in natural self-regulatory immune responses coupled with mucosa-derived TRYCAT pathway activation",
        "Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to Picolinic, Xanthurenic, and Quinolinic acid",
        "Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: Results of supervised Mach Learn",
        "In schizophrenia, depression, anxiety, and Physiosomatic symptoms are strongly related to psychotic symptoms and excitation, impairments in episodic memory, and increased production of neurotoxic tryptophan catabolites: A multivariate and machine learning study",
        "The positive and negative syndrome scale (PANSS) for schizophrenia",
        "Cognitive impairment in schizophrenia",
        "The schedule for the deficit syndrome: an instrument for research in schizophrenia",
        "Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain",
        "Sex differences in schizophrenia",
        "Free radicals, antioxidants and functional foods: impact on human health",
        "Partial least squares (PLS) structural equation modeling (SEM) for building and testing behavioral causal theory: when to choose it and how to use it",
        "Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine",
        "Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression",
        "Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers",
        "Major differences in neuro-oxidative and neuro-nitrosative stress pathways between major depressive disorder and types I and II bipolar disorders",
        "Cognitive functioning and employment in severe mental illness",
        "Relationship of cognition and psychopathology to functional impairment in schizophrenia",
        "Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours",
        "The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the quality of life scale",
        "Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic Na\u00efve first episode psychosis",
        "High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance",
        "Oxidative stress in drug na\u00efve first episode psychosis and antioxidant effects of risperidone",
        "Executive functioning in schizophrenia",
        "The brief psychiatric rating scale",
        "Lifetime antecedents of cognitive reserve",
        "Structural equation modeling with the SmartPLS",
        "SmartPLS 3",
        "Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients",
        "The relationship between experiential deficits of negative symptoms and subjective quality of life in schizophrenia",
        "Quality of life in chronic fatigue syndrome",
        "Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression",
        "Eotaxin, an endogenous cognitive deteriorating chemokine (ECDC), is a major contributor to cognitive decline in Normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in schizophrenia patients",
        "Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia",
        "The macrophage-T-lymphocyte theory of schizophrenia: additional evidence",
        "The role of negative symptoms and cognitive dysfunction in schizophrenia outcome",
        "An introduction to partial least squares regression",
        "Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: A meta-analytic investigation",
        "Quality of life and cognitive dysfunction in people with schizophrenia",
        "Quality of life of patients with chronic fatigue syndrome",
        "The consortium to establish a registry for Alzheimer's disease (CERAD). Part V. a normative study of the neuropsychological battery",
        "Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL)",
        "A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale)"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Plovdiv",
            "@id": "60031890",
            "affilname": "Medical University of Plovdiv",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031890",
            "affiliation-country": "Bulgaria"
        },
        {
            "affiliation-city": "Geelong",
            "@id": "60018805",
            "affilname": "Deakin University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018805",
            "affiliation-country": "Australia"
        }
    ],
    "funding": [
        "Chulalongkorn University Centenary Academic Development Project",
        "Asahi Glass Foundation"
    ]
}